Table 3. Total, stratified and sensitivity analysis of NOS3 G894T polymorphism and the AD susceptibility.

Summary	Na	Cases/Controls	Q Test			I2,%	Odds Ratio	95% Confidence Interval	P for Z testc	P for interactiond
			χ2	df	P Valueb
All studies	23	5,670/5,046	44.07	22	0.003	50.1	1.18	1.04, 1.35	0.010	-
Subgroup analysis
Time of AD onset										0.049
Early	8	706/1,525	4.17	7	0.760	0.0	1.02	0.83, 1.26	0.834
Late	14	2,568/2,866	37.63	13	<0.001	65.5	1.33	1.07, 1.66	0.010
Ethnic descent										0.246
Caucasiane	17	4,051/3,294	35.04	16	0.004	54.3	1.15	0.99, 1.34	0.075
Asian	6	1,619/1,752	7.68	5	0.175	34.9	1.31	1.03, 1.67	0.030
APOE										0.925
ε4+	5	347/161	5.74	4	0.220	30.3	1.25	0.82, 1.91	0.304
ε4-	5	560/884	9.74	4	0.045	58.9	1.22	0.95, 1.56	0.116
HWE in controls										0.065
Yes	18	4,580/3,938	29.16	17	0.033	41.7	1.12	1.02, 1.23	0.021
No	5	1,090/1,108	11.51	4	0.021	65.3	1.48	1.04, 2.12	0.030
Control type										0.912
PB	19	4,410/4,149	36.99	18	0.005	51.3	1.20	1.03, 1.39	0.018
HB	4	1,260/897	7.07	3	0.070	57.5	1.15	0.85, 1.54	0.367
Date of publication										0.139
≤2003	11	2,363/1,890	21.51	10	0.018	53.5	1.09	0.90, 1.34	0.380
>2003	12	3,307/3,156	20.37	11	0.040	46.0	1.27	1.08, 1.50	0.005
Quality score										0.599
Low	10	2,660/1,970	20.04	9	0.018	55.1	1.16	0.94, 1.43	0.158
High	13	3,010/3,076	23.75	12	0.022	49.5	1.21	1.02, 1.43	0.031
Sensitivity analyses										—
Minimal	22	−/−	38.46	21	0.011	45.4	1.16	1.02, 1.31	0.025
Maximal	22	−/−	39.82	21	0.008	47.3	1.21	1.06, 1.38	0.004

CI: Confidence interval; PB: population-based; HB: hospital-based.

^aNumber of comparisons.

^bP value of Q-test for between study heterogeneity test.

^cP-value of Z-test for significant test.

^dP value of Q-test for between sub-group heterogeneity test.

^eAfrican descents were excluded from one study by Akomolafe A et al.²⁷.